(Q37691163)

English

A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis

scientific article published on 25 October 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis (English)

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

1 reference

based on heuristic

inferred from title

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

David A Martin

1

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Melvin Churchill

2

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Luis Flores-Suarez

3

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Mario H Cardiel

4

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Daniel Wallace

5

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Richard Martin

6

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Kristine Phillips

7

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Jeffrey L Kaine

8

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Hua Dong

9

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

David Salinger

10

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Erin Stevens

11

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Chris B Russell

12

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

James B Chung

13

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

publication date

25 October 2013

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Arthritis Research and Therapy

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

15

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

5

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

R164

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

https://scigraph.springernature.com/pub.10.1186/ar4347

0 references

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3979125

23 August 2017

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3979125

23 August 2017

The pathogenesis of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3979125

23 August 2017

Recent advances in the IL-17 cytokine family

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3979125

23 August 2017

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3979125

23 August 2017

LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3979125

23 August 2017

Interleukin-17 and type 17 helper T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3979125

23 August 2017

Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3979125

23 August 2017

Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3979125

23 August 2017

IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3979125

23 August 2017

Targeting IL-17 and TH17 cells in chronic inflammation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3979125

6 September 2017

Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3979125

23 June 2018

Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3979125

1 September 2018

Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3979125

1 September 2018

Updated recommendations for the treatment of rheumatoid arthritis: another step on a long road

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3979125

1 September 2018

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

1 reference

https://api.crossref.org/works/10.1186%2FAR4347

21 January 2018

High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism

1 reference

https://pubmed.ncbi.nlm.nih.gov/24286136

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24286136

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37691163&oldid=1723226943"